BioPortfolio Biotechnology Pharmaceutical Healthcare Medical Life Science Drug Discovery Disease

Pharmacyclics Incorporated

Pharmacyclics, Inc. is a pharmaceutical company developing energy-potentiating drugs to improve radiation therapy andchemotherapy of cancer, and to enable or improve the photodynamic therapy of certain cancers, atherosclerotic cardiovascular disease and retinal diseases. The Company's products are ring-shaped small molecules, called "texaphyrins,"

which are patented agents derived from Pharmacyclics' versatile technology platform for designing and synthesizing energy-potentiating drugs. These texaphyrins localize in cancer cells and atherosclerotic plaque, where they can be activated by forms of energy, including X-ray, chemical and light, to selectively eliminate diseased tissue. The Company's lead texaphyrin-based product candidates are Gd-Tex, a gadolinium texaphyrin molecule being developed for use as a radiation sensitizer (initially in the treatment of brain metastases) and chemosensitizer; LUTRIN(TM) photosensitizer, a lutetium texaphyrin molecule being developed as a photosensitizer for use in photodynamic therapy of cancer; ANTRIN(TM) photosensitizer, a lutetium texaphyrin molecule being developed as a photosensitizer for use in the photoangioplasty of atherosclerosis; and OPTRIN(TM) photosensitizer, a lutetium texaphyrin molecule being developed as a photosensitizer for use in photodynamic therapy of age related macular degeneration (ARMD).


Contact Details:
995 East Arques Avenue
Sunnyvale
CA
94086-4521
United States of America
Tel:408 774 0330
Fax:408 774 0340
Email:info@pcyc.com
WWW:

www.pcyc.com/




Loading...

Recent Publications by Pharmacyclics Incorporated:

ATM activation and signalling under hypoxic conditions.
The ATM kinase has been shown previously to respond to the DNA-damage...
5th November, 2008
The Cancer Research UK/MRC Gray Institute for Radiation Oncology and Mol Cell Biol. 2008 Nov 3.
DOI Direct Link
Synthesis and anticancer properties of water-soluble zinc ionophores.
Several water-solubilized versions of the zinc ionophore...
6th August, 2008
Pharmacyclics, Inc, Cancer Res. 2008 Jul 1;68(13):5318-25.
DOI Direct Link
A novel histone deacetylase 8 (HDAC8)-specific inhibitor PCI-34051 induces apoptosis in T-cell lymphomas.
We have developed a potent, histone deacetylase 8 (HDAC8)-specific...
24th June, 2008
Department of Cancer Biology, Pharmacyclics Inc., Sunnyvale, CA 94085, Leukemia. 2008 May;22(5):1026-34. Epub 2008 Feb 7.
DOI Direct Link
HDAC inhibitor PCI-24781 decreases RAD51 expression and inhibits homologous recombination.
Histone deacetylase (HDAC) inhibitors such as the phenyl hydroxamic acid...
19th January, 2008
Pharmacyclics, Inc., Sunnyvale, CA 94085-4521, USA. Proc Natl Acad Sci U S A. 2007 Dec 4;104(49):19482-7. Epub 2007 Nov 27.
DOI Direct Link
Validation and use of three complementary analytical methods (LC-FLS, LC-MS/MS and ICP-MS) to evaluate the pharmacokinetics, biodistribution and stability of motexafin gadolinium in plasma and tissues.
Liquid chromatography-fluorescence (LC-FLS), liquid chromatography-tandem...
9th May, 2007
Pharmacyclics, Inc., 995 E. Arques Avenue, Sunnyvale, CA 94085, USA. Anal Bioanal Chem. 2006 May;385(2):345-56. Epub 2006 Apr 12.
DOI Direct Link

View more Pharmacyclics Incorporated research publications.

BioNews Results for Pharmacyclics Incorporated:

Pharmacyclics Announces Completion Of Phase 1 Clinical Trial Of Factor VIIa Inhibitor PCI-27483
Medical News Today:  Nov 27 2008 8:51AM Matching: pharmacyclics
Pharmacyclics completes Phase I study of Factor VIIa inhibitor
Pharmaceutical Business Review:  Nov 27 2008 8:38PM Matching: pharmacyclics
Pharmacyclics Announces Completion of Phase 1 Clinical Trial of Factor VIIa Inhibitor PCI-27483
Pharma Live:  Nov 25 2008 8:59PM Matching: pharmacyclics
Pharmacyclics Announces Completion of Phase 1 Clinical Trial of Factor VIIa Inhibitor PCI-27483
Therapeutics Daily:  Nov 25 2008 3:21PM Matching: pharmacyclics
Examine this Essential and Comprehensive Report on Brain Tumors Resulting from Cancer
Pharmacy Choice:  Nov 9 2008 3:56AM Matching: pharmacyclics
Promote your company here: BioNewsCast - Press Release Distribution

View more Pharmacyclics Incorporated news.

Pharmacyclics Incorporated Patents:

US Patent No.Title
5530122 Method of isolating texaphyrins
5601802 Methods of MRI enhancement using compounds having improved functionalization
5607924 DNA photocleavage using texaphyrins
5622946 Radiation sensitization using texaphyrins
5632970 Fluoresence detection using texaphyrins

View more Pharmacyclics Incorporated patents.

Pharmacyclics Incorporated (PCYC) Financial information Links from Barchart

PCYC Quote from from Barchart.com
PCYC Chart from from Barchart.com
PCYC Profile from from Barchart.com
PCYC Opinion from from Barchart.com

View more Pharmacyclics Incorporated finance information.

Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.

This page has been viewed 194 times since April 2007, the link to the organisation's website has been followed 36 times

Recent Search Terms used to find this page: Photoangioplasty | Antrin Pharmacyclics | Sapphyrins Pharmacyclics | lc-fls chromatography | stability of motexafin | Pharmacyclics Incorporated | .

Search for more companies in Sunnyvale

Search for more companies in CA



This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.
BioPortfolio search results for Pharmacyclics Incorporated

  Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.

All rights reserved. All other trademarks recognized.
Copyright 1997-2008 - BioPortfolio Limited.